Sign In
Buy SGMT
$7.06
-0.0400 (-0.563%)
At Close: Jun 23, 2026
SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
10:56am, Thursday, 04'th Jun 2026
After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc. (SGMT), indicating that the stock has found support. This, combined with an upward trend in earnings
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
07:00am, Wednesday, 27'th May 2026
Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid reduc
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
10:55am, Thursday, 21'st May 2026
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat
02:19pm, Thursday, 14'th May 2026
Sagimet Biosciences receives a Buy rating, driven by denifanstat's potential in MASH and acne, despite higher risk. Denifanstat met all endpoints in Phase 2b MASH and Phase 3 China acne trials, suppor
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
07:00am, Wednesday, 13'th May 2026
SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
07:30am, Tuesday, 12'th May 2026
Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 Fi
Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
01:01pm, Tuesday, 05'th May 2026
Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
10:55am, Tuesday, 05'th May 2026
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem
Why Is Sagimet Biosciences Stock Trading Higher On Monday?
01:48pm, Monday, 27'th Apr 2026
Sagimet Biosciences Inc. (NASDAQ:SGMT) shares are surging on Monday, up 44% as the company announced strategic updates regarding its clinical trials.
Why Sagimet Biosciences Stock Is Soaring Today
11:40am, Monday, 27'th Apr 2026
The biopharma company confirmed it's still aiming at the United States' acne-treatment market.
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
07:15am, Monday, 27'th Apr 2026
SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli
Sagimet Biosciences Provides Strategic and Corporate Updates
07:00am, Monday, 27'th Apr 2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ong
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts
02:22am, Monday, 27'th Apr 2026
Shares of Sagimet Biosciences Inc. (NASDAQ: SGMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are presently covering the company, Ma
